Pharmaceuticals for performance adjustment during regular physical activity

Capa


Citar

Texto integral

Resumo

Reasonable pharmacological support for elite athletes is an important issue not yet addressed. Therefore, it is required to find advanced approaches and means to boost physical and functional performance during regular physical activity. It is well known that active sports change the functional performance associated with adaptation to physical and psycho-emotional stress and, consequently, the degree of stress on regulatory mechanisms. Thus, there is a need to develop new, more advanced medical and biological technologies to enhance sports training. Scholars distinguish five different classes of performance-enhancing agents, including nutritional, physiological, psychological, pharmacological, and biomechanical. To enhance training performance, both physiological methods and pharmaceuticals are used. However, it should be noted that the drugs can also have adverse effects, primarily on the central nervous system, metabolism, heart, liver, kidneys, blood, and the human hormonal system. Reasonable pharmacological support for elite athletes is important. The review presents contemporary data on the means used to correct the body’s adaptive mechanisms, replenish expended energy, and restore performance during regular physical stress.

Texto integral

Interest in the issues of medical support for high-performance sports does not wane. One of the areas of the sports training process is the justification of the use of methods for correcting

performance during systematic physical activity. To enhance this process, not only physiological methods of influence (normobaric and hyperbaric oxygenation, hypobaric and normobaric hypoxic training, exposure to pulsed electric current) are used, but also

pharmacological drugs 11, 2, 3, 4, 5, 6, 71. At the same time, it should be noted that the use of drugs can also have undesirable side effects, primarily on the central nervous system, metabolic processes, heart, liver, kidneys, blood, and the human hormonal system [8, 9, 10]. In addition, many drugs (anabolic steroids, growth factors, hormones, psychostimulants, narcotic substances, etc.) have already been included in the list of prohibited drugs (VADA) [11, 1, 2]

and others may be included there in the near future [3, 4].

Reasonable pharmacological support of highly qualified athletes remains an important problem. Therefore, the search for modern approaches and means that increase physical performance and functional state during systematic physical activity does not lose its relevance.

×

Sobre autores

Elena Bolshova

Lesgaft National State University of Physical Education, Sports and Health

Email: bolshovaev@mail.ru
Código SPIN: 9831-2927
Rússia, Saint Petersburg

Petr Shabanov

Institute of Experimental Medicine

Autor responsável pela correspondência
Email: pdshabanov@mail.ru
Código SPIN: 8974-7477

MD, Dr. Sci. (Medicine), Professor

Rússia, Saint Petersburg

Bibliografia

  1. Makarova GA, Achkasov EE, Loktev SA. Intersystem analysis of risk factors as a basis for professionally oriented sports medicine. Sports Medicine: Research and Practice. 2016;6(1):106–111. EDN: WBBJCJ
  2. Mashkovskii MD. Medicinal products. 16th ed. Moscow: Novaia Volna; 2014. 1216 p. (In Russ.) ISBN: 978-5-7864-0218-7
  3. Pitkevich ES, Lositskii EA, Krestianinova TY, et al. Pharmacological correction of working capacity in sports: methodological recommendations. Vitebsk: VSU named after Masherov PM; 2013. 52 p. EDN: SHQHWE
  4. Potupchik T, Veselova O, Evert L, et al. Application of peptide bioregulators in case of physical excretion. Sports Medicine: Research and Practice. 2017;7(1):53–59. doi: 10.17238/ISSN2223-2524.2017.1.53 EDN: WCIICM
  5. Russian Register of Medicinal Products. Drug Encyclopedia. 28th ed. Vyshkovskii GL, ed. Moscow: Vedanta; 2019. 860 p. (In Russ.)
  6. Rodichkin PV, Shabanov PD. Use of antihypoxants in different sports. Psychopharmacology and Biological Narcology. 2007;7(2):1919. (In Russ.)
  7. Sapronov NS, Khnyshenko LK, Shelemeha SE. Stress-induced metabolic disorders and their pharmacological correction. Saint Petersburg; 2009. 238 p. (In Russ.) ISBN: 978-5-89497-009-7 EDN: QLUTUN
  8. Medvedev YV, Tolstoi AD. Hypoxia and free radicals in the development of pathological conditions of the body. Moscow: Terra-kalender promotion; 2000. 227 p. (In Russ.) ISBN: 5-275-00072-3
  9. Rodichkin PV. Regulation of motor functions in elite athletes and its optimization with the help of adaptogens, antihypoxants and hyperbaric oxygenation [dissertation abstract]. Saint Petersburg; 2004. 48 p. (In Russ.) EDN: NHRVND
  10. Troegubova NA, Rylova NV, Gilmutdinov RR, et al. Metabolism magnesium and zinc of sportsments. Modern Problems of Science and Education. 2014;(4):323. EDN: STRPJV
  11. Prohibited List 2009. World Anti-Doping Agency. (WADA). International Standard. Moscow: Physical education and sports; 2009. 17 p. (In Russ.)
  12. Seredanin SB. The pharmacological regulation of emotional-and-stress reactions. Annals of the Russian Academy of Medical Sciences. 2003;(12):35–38. EDN: OITSAP
  13. Silkina IV, Aleksandrin VV, Ganshina TS, et al. Afobazole increases cerebral blood flow in rats with global brain ischemia. Experimental and Clinical Pharmacology. 2004;67(5):9–12. EDN: SZOSYZ
  14. Sudakov KV. Stress: postulates, analysis from the perspective of the general theory of functional systems. Pathological Physiology and Experimental Therapy. 1992;(4):86–93. (In Russ.)
  15. Talibov AKH, Nozdrachev AD, Shabanov PD. Functional cardiology in sports. Saint Petersburg: Art-Ekspress; 2020. 240 p. (In Russ.) ISBN: 978-5-4391-0610-3 EDN: XNCQOA
  16. Voronina TA, Seredanin SB. Prospects for search for new anxiolytics. Experimental and Clinical Pharmacology. 2002;65(5):4–17. EDN: SVZSNT
  17. Lotonenko AV, Golovko NG, Bugakov AI. Basic methods of ”modes” of physical activity. Physical Culture and Health. 2014;(4):38–40. EDN: THAYEF
  18. Liubchenko PN. Prevention of and coping with professional stress. Clinical Medicine. 2007;85(9):22–27. EDN: JUKIOD
  19. Okovityi SV, Radko SV. The application of succine in sports. Problems of Balneology, Physiotherapy, and Exercise Therapy. 2015;92(6):59–65. EDN: VIYYBB
  20. Radzhapkadiev RM, Margarita MK, Evstratova VS, et al. L-carnitine: properties and perspectives for use in sports practice. Problems of Nutrition. 2015;84(3):4–12. EDN: UBEKZT
  21. Okovityi SV, Radko SV, Shustov EB. Succinate receptors (sucnr1) as a potential target for pharmacotherapy. Pharmaceutical Chemistry Journal. 2015;49(9):3–7. EDN: ULGYVH
  22. Silkina IV, Zenina TA, Seredanin SB, et al. Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia. Experimental and Clinical Pharmacology. 2006;69(4):47–50. EDN: SZXCRT
  23. Smirnov AV, Nesterova OB, Golubev RV. Succinic acid and its application in medicine. Part I. Succinic acid: metabolite and regulator of metabolism of the human body. Nephrology. 2014;18(2):33–41.
  24. Gudasheva TA. Strategy for the development of dipeptide drugs. Annals of the Russian Academy of Medical Science. 2011;(7):8–16. EDN: NZARZT
  25. Korotkov SA. Experimental study of pharmacokinetics and biotransformation of the new dipeptide nootropic noopept. [dissertation abstract]. Moscow; 2003. 32 p. (In Russ.) EDN: NMKJRD
  26. Pitkevich ES, Lositskii EA, Martinovskii A. Pharmacological means for correcting physical performance. Vitebsk Medical Journal. 2002;1(2):33–41. EDN: VJFEIS
  27. Zarubina IV, Shabanov PD. Pharmacological protection of the brain, heart and liver from acute hypoxia. Medical Academic Journal. 2003;3(2):49–57. (In Russ.)
  28. Zarubina IV. Modern view on pathogenesis of hypoxia and its pharmacological corection. Reviews on Clinical Pharmacology and Drug Therapy. 2011;9(3):31–48. EDN: OUNJLR
  29. Zarubina IV, Shabanov PD. Neuroprotective effects of the antihypoxants amtizol and trimetazidine in acute hypoxia and cerebral ischemia. Neurosciences. 2005;(5):8–11. (In Russ.)
  30. Zarubina IV, Pavlova TV, Shabanov PD. Antihypoxic effects of cortexin in healthy volunteers. Psychopharmacology and Biological Narcology. 2007;7(1):1700. (In Russ.)
  31. Okunevich IV, Khnyschenko LK, Shabanov PD. Influence of hypoxen on the data changing of lipid metabolsim in the experimantal dislipoproteinemia. Reviews of Clinical Pharmacology and Drug Therapy. 2014;12(3):26–29. EDN: TEONUJ
  32. Shilov AM, Sviatov IS, Chubarov MV, et al. Results of the use of magnesium-containing drugs for the treatment and prevention of hyper- and dyslipidemia. Clinical Medicine. 1998;76(4):35–37. (In Russ.)
  33. Shustov EB, Okovityi SV. Ex-orphan receptors as targets for potential medicines. Biomedicine. 2015;(2):15–29. EDN: TYYPPH
  34. Shmidt JO, Lysenko AV. Peptide bioregulation in professional sports as an alternative to doping. In: Physical Culture, Sport, Health and Longevity. IV International Scientific Conference dedicated to the 100th anniversary of Southern Federal University. 2015. P. 261–266. EDN: XYCUEV
  35. Ganapolskii VP, Shabanov PD. Meteoadaptogenic properties of antihypoxic drugs. Experimental and Clinical Pharmacology. 2009;72(6):36–41. EDN: TNKCHX
  36. Levchenkova OS, Novikov VE, Pozhilova EV. Pharmacodynamics of antihypoxants and their clinical use. Reviews of Clinical Pharmacology and Drug Therapy. 2012;10(3):3–12. EDN: QZKXOV
  37. Shabanov PD, Lebedev AA, Stetsenko VP, et al. Pharmacology of drugs of peptide structure. Psychopharmacology and Biological Narcology. 2008;8(3-4):2399–2425. EDN: KHQGRX
  38. Shabanov PD, Lebedev AA, Stetsenko VP, et al. Comparison of behavioral effects of cortexin and cerebrolysin injected into brain ventricles. Bulletin of Experimental Biology and Medicine. 2007;143(4):414–418. EDN: HZFNBN
  39. Mirzoian RS, Khailov NA, Ganshina TS. Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation. Experimental and Clinical Pharmacology. 2010;73(5):2–7. EDN: TNKBNN
  40. Ostrovskaya RU, Gudasheva TA, Caplina AP, et al. Noopept stimulates the expression of NGF and BDNF in the rat hippocampus. Bulletin of Experimental Biology and Medicine. 2008;146(9):310–313. EDN: JUXVKV
  41. Voronina TA. Mexidol: spectrum of pharmacological effects. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86–90. EDN: PTUPBT
  42. Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(4):81–87. doi: 10.17116/jnevro202012004181 EDN: XJLWDR
  43. Afanasiev VV. Clinical pharmacology of reamberin. Saint Petersburg; 2005. 44 p. (In Russ.) ISBN: 5-94542-149-9 EDN: QLKSTF
  44. Gromova OA, Torshin IY, Stakhovskaya EG, et al. Experience with mexidol in neurological practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):94–104. doi: 10.17116/jnevro201811810197 EDN: YOYQVN
  45. Kapitsa IG, Ivanova EA, Voronina TA. Effect of mexidol on physical and mental performance under stressogenic conditions in experiment. Pharmacokinetics and Pharmacodynamics. 2019;(1):12–17. doi: 10.24411/2587-7836-2019-10034 EDN: SCVYBH
  46. Bizienkova MK, Romantsov MG, Afanasieva GA, et al. Cytoflavin as the medication of effective correction of metabolic disorders upon hypoxia of different genesis. Advances in Current Natural Sciences. 2006;(4):28. EDN: IIZHJR
  47. Kondrashova MN. Hormone-like action of succinic acid. Problems of Biological, Medical and Pharmaceutical Chemistry. 2002;(1):7–12. (In Russ.)
  48. Gavrilova E, Gunina L. Biologically active supplements in the system of pharmacological promotion of elite hockey-player training process. Science in Olympic Sports. 2014;(3):52–61. EDN: TFYSJJ
  49. Ivanova YM, Sharykin AS, Pavlov VI, et al. Bradycardia and performance indicators in adult hockey players. Problems of Balneology, Physiotherapy, and Exercise Therapy. 2016;93(2-2):82. EDN: XWPCYD
  50. Sudakov KV. Systemic mechanisms of emotional stress. Moscow: Meditsina; 1981. 230 p. (In Russ.)
  51. Rabinovich SA. Modern technologies of local anesthesia in dentistry. Moscow; 2000. 144 p. ISBN: 5-89004-092-8
  52. Karkishchenko NN, Uiba VV, Karkishchenko VN, et al. Essays on sports pharmacology. Vectors of pharmacoprotection. Vol. 2. Moscow, Saint Petersburg: Aising; 2014. 448 p. (In Russ.) ISBN: 978-5-91753-077-2
  53. Gromova OA. Physiological role and significance of magnesium in therapy (a review). Therapeutic Archive. 2004;76(10):58–62. EDN: OKJSCB
  54. Chekman IS, Gorchakova NA, Nikolai SL. Magnesium in medicine. Chisinau: Stiinca; 1992. 102 p. ISBN: 5-376-01316-2
  55. Shabanov PD. Hypoxia and antihypoxants. Bulletin of the Russian Military Medical Academy. 2003;(1(9)):111–121. (In Russ.) EDN: FDWDFR
  56. Shustov EB. General questions of methodology of elite sport and its pharmacological support. Bulletin of the Russian Academy of Natural Sciences (Saint Petersburg). 2015;(3):108–114. EDN: UOSUKR
  57. Iliutik AV, Gilep IL. Biochemical fundamentals of athletes’ nutrition. Minsk: BSUPC; 2020. 64 p. ISBN: 978-985-569-498-5
  58. Lebedev AA, Ganapolskii VP, Pavlenko VP, et al. Comparison of central effects of cortexin and cerebrolysin after their administration into cerebral ventriculi or systematically (intraperitoneally). Psychopharmacology and Biological Narcology. 2006;6(3):1275–1283. EDN: HUAGQP
  59. Shabanov PD, Zarubina IV, Novikov VE, et al. Metabolic correctors of hypoxia. Saint Petersburg: Inform-Navigator; 2010. 912 p. (In Russ.) ISBN: 978-5-9902181-2-3 EDN: QLYCVF

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Eco-Vector, 2025

Creative Commons License
Este artigo é disponível sob a Licença Creative Commons Atribuição–NãoComercial–SemDerivações 4.0 Internacional.
Сетевое издание зарегистрировано как СМИ Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор): ЭЛ № ФС77-88807 от 13.12.2024.